Restoration of Epigenetically Silenced Sulfatase 1 Expression by 5-Aza-2′-Deoxycytidine Sensitizes Hepatocellular Carcinoma Cells to Chemotherapy-Induced Apoptosis
暂无分享,去创建一个
C. Moser | L. Roberts | N. Tsuchiya | R. Jenkins | G. Lomberk | Chunling Hu | I. Aderca | J. Lai | Hongzhi Zou | A. Shire | K. Gulaid | A. Oseini | Omar Warsame | Ileana Aderca | Jinping Lai
[1] C. Moser,et al. Activation of the transforming growth factor‐β/SMAD transcriptional pathway underlies a novel tumor‐promoting role of sulfatase 1 in hepatocellular carcinoma , 2015, Hepatology.
[2] V. Santini,et al. Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3 , 2013, Epigenetics.
[3] B. Ren,et al. Genome organization and long-range regulation of gene expression by enhancers. , 2013, Current opinion in cell biology.
[4] Antoine H. F. M. Peters,et al. H3K9/HP1 and Polycomb: two key epigenetic silencing pathways for gene regulation and embryo development. , 2013, Current topics in developmental biology.
[5] A. Goel,et al. Up‐regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer , 2012, The Journal of pathology.
[6] C. Chenu,et al. Mammalian Sulf1 RNA alternative splicing and its significance to tumour growth regulation , 2012, Tumor Biology.
[7] H. Nagase,et al. Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development , 2011, BMC Genomics.
[8] S. Lemon,et al. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer , 2011, Oncogene.
[9] J. Chien,et al. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. , 2011, Cancer research.
[10] Chunling Hu,et al. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: Associated signaling pathways, tumor phenotypes, and survival , 2011, Genes, chromosomes & cancer.
[11] G. Mills,et al. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer , 2011, Journal of experimental & clinical cancer research : CR.
[12] B. Klein,et al. SULFs in human neoplasia: implication as progression and prognosis factors , 2011, Journal of Translational Medicine.
[13] T. Dragani,et al. Risk of HCC: genetic heterogeneity and complex genetics. , 2010, Journal of hepatology.
[14] S. Chanock,et al. Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer , 2010, PloS one.
[15] Koichi Hirata,et al. Gene expression analysis identifies over‐expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer , 2010, Genes, chromosomes & cancer.
[16] R. Chung,et al. Viral hepatocarcinogenesis , 2010, Oncogene.
[17] S. Sanderson,et al. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. , 2009, Journal of hepatology.
[18] S. Kalloger,et al. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. , 2009, Cancer research.
[19] Hai-Meng Zhou,et al. Promoter hypermethylation correlates with the Hsulf‐1 silencing in human breast and gastric cancer , 2009, International journal of cancer.
[20] Tara L. Kieffer,et al. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .
[21] L. Roberts,et al. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. , 2008, Future oncology.
[22] Dawn R. Chin,et al. Transforming Growth Factor-β1 Induces Heparan Sulfate 6-O-Endosulfatase 1 Expression in Vitro and in Vivo* , 2008, Journal of Biological Chemistry.
[23] S. Thorgeirsson,et al. Sulfatase 2 up‐regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma , 2008, Hepatology.
[24] H. El‐Serag. Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[25] J. Chien,et al. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance , 2007, Oncogene.
[26] S. Pradhan,et al. Functional cooperation between HP1 and DNMT1 mediates gene silencing. , 2007, Genes & development.
[27] J. Chien,et al. Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer* , 2007, Journal of Biological Chemistry.
[28] M. Fraga,et al. The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.
[29] J. Chien,et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. , 2006, Cancer research.
[30] Chunrong Yu,et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. , 2006, Gastroenterology.
[31] S. Sanche,et al. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. , 2006, Leukemia research.
[32] M. Thomas,et al. Opportunities for targeted therapies in hepatocellular carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Friess,et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer , 2005, Molecular Cancer.
[34] B. Dörken,et al. Induction of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms , 2005, Leukemia.
[35] David I. Smith,et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma , 2004, Oncogene.
[36] David I. Smith,et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. , 2004, Gastroenterology.
[37] David I. Smith,et al. Loss of HSulf-1 Up-regulates Heparin-binding Growth Factor Signaling in Cancer* , 2003, Journal of Biological Chemistry.
[38] D. Parkin,et al. Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.
[39] H. El‐Serag,et al. Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.
[40] D. Bostwick,et al. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. , 1997, Cancer research.
[41] S. Cross,et al. Purification of CpG islands using a methylated DNA binding column , 1994, Nature Genetics.